

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**

**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 6185)**

**INSIDE INFORMATION**

**PROGRESS OF PHASE III CLINICAL TRIAL FOR  
RECOMBINANT NOVEL CORONAVIRUS VACCINE  
(ADENOVIRUS TYPE 5 VECTOR)**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company noticed that The Lancet published a research article titled “*Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial*” in relation to results of phase III clinical trial for our Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (the “**Ad5-nCoV**”, trade name: Convidecia). The Company hereby announces that, the final analysis data of the international multicenter phase III clinical trial of Ad5-nCoV shows that Ad5-nCoV is 57.5% effective against symptomatic COVID-19 infection and 91.7% effective against severe disease 28 days after single dose vaccination, and is 63.7% effective against symptomatic COVID-19 infection and 96.0% effective against severe disease 14 days after single dose vaccination. The efficacy of Ad5-nCoV has met the relevant technical standards laid out by the World Health Organization. In the primary safety analysis, there was no serious vaccine-related adverse events or deaths among trial participants. One dose of Ad5-nCoV is efficacious and safe in healthy adults aged 18 years and older. For further details of the research article, please refer to [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)02753-7/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02753-7/fulltext).

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, December 24, 2021

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.*